- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04403100
Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"
Hydroxychloroquine and Lopinavir/ Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms: "The Hope Coalition"
Study Overview
Status
Conditions
Detailed Description
In December 2019 a series of viral pneumonia cases were reported in the city of Wuhan, China. A new subtype of coronavirus has been identified as the causative agent of this condition. On February 11, 43,103 cases had already been described and on this day the World Health Organization (WHO) named this disease as COVID-19. With. The disease had spread out to several countries on different continents and on March 11, WHO declared a state of worldwide pandemic. Today (April 25, 2020) there are 2,719,897 cases and 187,705 deaths documented, with a global case-fatality ratio of 6.9%.
To date, no treatment has been identified as effective in combating this disease which has been identified as with high mortality, therefore there are no specific therapeutic options. So far, efforts have been focused on the treatment of patients hospitalized with dyspnea and, although several promising drugs are being evaluated, none has demonstrated effectiveness in reducing morbidity and mortality at this stage of the disease, suggesting that perhaps the best time to use medications either before the onset of severe symptoms of respiratory distress.
Thus, we propose the use of two drugs which experimentally have shown activity against SARS-CoV2 and being used in severely ill patients with COVID-19. Our hypothesis is that perhaps using such drugs before onset of complications will allow better outcomes on this patient population.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Gilmar Reis, MD, PhD
- Phone Number: +5531332416574
- Email: greisbh@uol.com.br
Study Contact Backup
- Name: Rosemary Oliveira, SC
- Phone Number: +5531992636703
- Email: roliveira@cardresearch.org
Study Locations
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil, 30150240
- Recruiting
- CARDRESEARCH - Cardiologia Assistencial e de Pesquisa
-
Belo Horizonte, Minas Gerais, Brazil, 30535901
- Not yet recruiting
- Pontifícia Universidade Católica de Minas Gerais
-
Contact:
- Eduardo Silva, MD, PhD
- Email: duduaugusto1@gmail.com
-
Principal Investigator:
- Eduardo Silva, MD, PhD
-
Betim, Minas Gerais, Brazil, 32600412
- Recruiting
- Fundo Municipal de Saúde de Betim
-
Contact:
- Daniela Silva, MD, PhD
- Phone Number: 5531984923130
- Email: daninhamed@yahoo.com.br
-
Principal Investigator:
- Daniela Silva, MD, PhD
-
Ouro Preto, Minas Gerais, Brazil, 35400000
- Not yet recruiting
- Universidade Federal de Ouro Preto
-
Contact:
- Leonardo Savassi, MD, PhD
- Email: leosavassi@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with RT-PCR diagnosis of COVID-19 or a clinical condition compatible with COVID-19 and respiratory symptoms, presenting:
A. Persistent dry cough associated with axillary temperature > 37.7 Celsius;
OR
B. Recent onset of Flu-like Respiratory Symptoms associated with dry cough
OR
C. Tomographic image compatible with COVID 19 infection;
2. Men and women aged > 50 years OR: Patients over 18 years of age with at least one of the following criteria
- Diabetes requiring oral medication or insulin.
- Arterial hypertension requiring at least 01 oral medication for treatment
- Known cardiovascular diseases (CHF of any etiology, documented Coronary Artery Disease, Clinically overt heart disease)
- Symptomatic chronic lung disease and/ or medically controlled
- Patients with a history of transplantation
- Patient with stage IV chronic kidney disease or on dialysis.
- Patients on current Immunosuppression and/or using corticosteroid therapy (equivalent to at least 10 mg of oral prednisone per day)
Willingness to comply with study related procedures
3. Ability to provide informed consent before any protocol-related procedures.
Exclusion Criteria:
- RT-PCR exam for COVID-19 negative during the screening visit.
- Patients with an acute respiratory condition compatible with COVID-19 being hospitalized;
- Patients with an acute respiratory condition and with moderate to high probability of not being a COVID infection 19;
- Dyspnea secondary to other acute and chronic respiratory causes or infections (eg, decompensated Chronic Obstructive Pulmonary Disease, acute bronchitis, pneumonia, primary pulmonary arterial hypertension);
Severe respiratory clinical condition, presenting at least ONE of the criteria below:
- Respiratory Rate> 28 / min;
- Arterial Oxygen Saturation < 92% with nasal oxygen therapy at 10 l/ min;
- PaO2 / FIO2 <300 mmHg
4. History of Cardiac Arrhythmia or Long QT Syndrome; 5. Use of Medications that are known to prolong QTc: Citalopram, Venlafaxine, Bupropion and with no possibility of suspension during the period of investigational medical product administration. 6. Inability to take oral medications; 7. Patients on continuous use of Amiodarone and / or PGE5 Inhibitors (Ex .: Sildenafil and similar). 8. Use of Digoxin, Cyclosporine, Cimetidine, Tamoxifen. 9. Use of anticonvulsants, antifungals, immunosuppressants other than corticotherapy. 10. Use of Hydroxychloroquine for other indications 11. Use of chemoprophylaxis for malaria. 12. Psoriasis in a form other than cutaneous 13. Porphyria 14. Use of protease inhibitors, ritonavir or Cobicistat 15. Clinical history of Liver Cirrhosis or Child-Pugh C classification; 16. Patients with a history of degenerative retinal diseases (patients with retinal diseases due to diabetes and hypertension can participate in the research); 17. Patient with a clinically relevant history of hearing loss; 18. Patients with known severe degenerative neurological diseases and / or severe mental illness; 19. Inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. Known hypersensitivity and / or intolerance to Hydroxychloroquine. 21. Hypersensitivity and / or intolerance Lopinavir / Ritonavir
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Hydroxychloroquine Sulfate
Hydroxychloroquine 400 mg.
Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days
|
Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days
|
ACTIVE_COMPARATOR: Lopinavir/ Ritonavir
Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days
|
tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
|
ACTIVE_COMPARATOR: Hydroxychloroquine plus Lopinavir/ Ritonavir
Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days Plus Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days |
Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days plus Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days |
PLACEBO_COMPARATOR: Placebo
Placebo Twice a day from day 1 through day 10. |
Placebo tablets - 01 tablet twice daily from day 01 through day 10.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants who were hospitalized for progression of COVID-19 disease
Time Frame: Measuring during 28-day period since randomization (Intention to treat analysis)
|
Hospitalization is defined as at least 24 hours of acute care in a hospital or similar acute care facility (emergency settings, temporary emergency facilities created for acute care of COVID-19 pandemic)
|
Measuring during 28-day period since randomization (Intention to treat analysis)
|
Proportion of participants who died due to COVID-19 progression and/ or complications
Time Frame: Measuring during 28-day period since randomization (Intention to treat analysis)
|
Measuring during 28-day period since randomization (Intention to treat analysis)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants with viral load change on 03, 07, 10 and 14 after randomization
Time Frame: Measuring during 14-day period since randomization
|
Viral load change on 03, 07, 10 and 14 after randomization (200 patients per arm)
|
Measuring during 14-day period since randomization
|
Time to clinical improvement
Time Frame: Measuring during 28-day period since randomization
|
Proportion of participants with clinical improvement, defined as normalization of temperature, Respiratory rate, SaO2, and cough relief (> 50% compared to baseline measured on a visual analog scale) in the last 72 hours.
|
Measuring during 28-day period since randomization
|
Time to clinical failure
Time Frame: Measuring during 28-day period since randomization
|
Proportion of participants with clinical improvement, defined as as time to need for hospitalization due to dyspnea, death, need for mechanical ventilation, shock and need for vasoactive amines;
|
Measuring during 28-day period since randomization
|
Hospitalization for any cause
Time Frame: Measuring during 28-day period since randomization
|
Proportion of participants with hospitalization for any cause
|
Measuring during 28-day period since randomization
|
Proportion of participants who died due to pulmonary complications
Time Frame: Measuring during 28-day period since randomization
|
Measuring during 28-day period since randomization
|
|
Proportion of participants who died due to cardiovascular complications
Time Frame: Measuring during 28-day period since randomization
|
Measuring during 28-day period since randomization
|
|
Proportion of participants who presented with adverse events
Time Frame: Measuring during 28-day period since randomization
|
Evaluation of adverse events evaluated as associated to any of study arms
|
Measuring during 28-day period since randomization
|
Time to improvement on respiratory scale symptoms
Time Frame: Measuring during 28-day period since randomization
|
Proportion of participants who presented sustained improvement on respiratory scale defined as at least 48 hours of improvement.
|
Measuring during 28-day period since randomization
|
proportion of non-adherent participants to any of study drugs
Time Frame: Measuring during 10-day period since randomization
|
Measuring during 10-day period since randomization
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gilmar Reis, MD, PhD, Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Severe Acute Respiratory Syndrome
- COVID-19
- Coronavirus Infections
- Infections
- Communicable Diseases
- Virus Diseases
- Respiratory Tract Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antirheumatic Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Antimalarials
- Ritonavir
- Lopinavir
- Hydroxychloroquine
Other Study ID Numbers
- COVID19_AMB_Brasil
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on Hydroxychloroquine Sulfate Tablets
-
SandozCompletedImmunosuppression | Rheumatism
-
Second Affiliated Hospital, School of Medicine,...RecruitingPrimary Sjögren's SyndromeChina
-
First Affiliated Hospital Xi'an Jiaotong UniversityCompletedCoronary Artery DiseaseChina
-
Shanghai First Maternity and Infant HospitalFudan University; Xinhua Hospital, Shanghai Jiao Tong University School of... and other collaboratorsNot yet recruitingRecurrent Miscarriage | Antiphospholipid SyndromeChina
-
Azidus BrasilSuspended
-
Azidus BrasilSuspended
-
Ravi Amaravadi, MDTerminatedCOVID-19United States
-
Health Institutes of TurkeyCompleted
-
Government of Punjab, Specialized Healthcare and...Harvard School of Public Health (HSPH); Forman Christian College, Pakistan; Services... and other collaboratorsTerminatedCOVID-19 | Coronavirus Infection | SARS-CoV-2 | Asymptomatic ConditionPakistan
-
Apsen Farmaceutica S.A.Federal University of São PauloWithdrawnCoronavirus Infections | SARS-CoV 2 | Pulmonary Disease | SARS (Severe Acute Respiratory Syndrome)Brazil